Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia

Never Waste a Good Crisis: Confronting Reproducibility in Translational Research

(2016) Daniel J. Drucker   Cell Metabolism

Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes

(2016) Rana Malek et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling

(2016) Matous Hrdinka et al.   Cell Reports

Unknown

(2016)   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors

(2015) Peter Canning et al.   CHEMISTRY & BIOLOGY

Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation

(2015) J. B. McPhee et al.   CLINICAL SCIENCE

Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance

(2015) E. Denou et al.   EMBO Molecular Medicine

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?

(2015) Athanasios Fountas et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production

(2015) Ueli Nachbur et al.   Nature Communications

Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance

(2014) Brandyn D. Henriksbo et al.   DIABETES

Enhanced vascular endothelial growth factor signaling in islets contributes to β cell injury and consequential diabetes in spontaneously diabetic Torii rats

(2014) Eri Mukai et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular disease

(2014) Gregory R Steinberg et al.   IMMUNOLOGY AND CELL BIOLOGY

In VivoInhibition of RIPK2 Kinase Alleviates Inflammatory Disease

(2014) Justine T. Tigno-Aranjuez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes

(2014) Yu-Mi Lim et al.   Nature Communications

Effect of Lipopolysaccharide on Inflammation and Insulin Action in Human Muscle

(2013) Hanyu Liang et al.   PLoS One

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

(2012) Adriano Salaroli et al.   ANNALS OF HEMATOLOGY

Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion

(2012) Stephen Fitter et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes

(2011) Ling Zhao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity

(2011) Summer M. Raines et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Inflammatory Mechanisms in Obesity

(2011) Margaret F. Gregor et al.   Annual Review of Immunology

The potential use of tyrosine kinase inhibitors in severe asthma

(2011) Vamsi P. Guntur et al.   Current Opinion in Allergy and Clinical Immunology

Inflammation Is Necessary for Long-Term but Not Short-Term High-Fat Diet-Induced Insulin Resistance

(2011) Y. S. Lee et al.   DIABETES

NOD1 Activators Link Innate Immunity to Insulin Resistance

(2011) J. D. Schertzer et al.   DIABETES

Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation

(2011) Maninder Sidhu et al.   INFLAMMATORY BOWEL DISEASES

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Believe it or not: how much can we rely on published data on potential drug targets?

(2011) Florian Prinz et al.   NATURE REVIEWS DRUG DISCOVERY

Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses

(2010) J. T. Tigno-Aranjuez et al.   GENES & DEVELOPMENT

Metabolic response to endotoxin in vivo in the conscious mouse: role of interleukin-6

(2010) Andrea Tweedell et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

(2010) Nicole M Agostino et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice

(2009) Patricia O. Prada et al.   DIABETES

Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice

(2009) M. S. Han et al.   DIABETES

Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor κb pathway

(2009) Carl F. Raetzsch et al.   HEPATOLOGY

Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes

(2009) Peter J. Little et al.   TheScientificWorldJOURNAL

Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice

(2008) P. D. Cani et al.   DIABETES

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

(2008) M. Breccia et al.   LEUKEMIA RESEARCH

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

(2007) Robert Hägerkvist et al.   CLINICAL SCIENCE